Intraop Medical Corp (IOPDQ) 0.0170 $IOPDQ
Firsthand Technology Value Fund Discloses Preliminary NAV of $27.43 Per Share as of March 31, 2014
GlobeNewswire - Thu Apr 17, 12:02PM CDT
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund"
, a publicly-traded venture capital fund that invests in technology and cleantech companies, today disclosed its preliminary net asset value (NAV) of $27.43 per share, as of March 31, 2014.
Firsthand Technology Value Fund Discloses Top Portfolio Holdings
GlobeNewswire - Mon Mar 10, 9:01AM CDT
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund", a publicly-traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2014 were Twitter, Facebook, IntraOp Medical, Turn, and AliphCom.
Firsthand Technology Value Fund Discloses Preliminary NAV of $28.31 Per Share as of December 31, 2013
GlobeNewswire - Thu Jan 16, 8:00AM CST
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund", a publicly-traded venture capital fund that invests in technology and cleantech companies, today disclosed its preliminary net asset value (NAV) of $28.31 per share, as of December 31, 2013. The Fund's estimated total return for 2013, based on the December 31, 2013 preliminary NAV, was 25.3%.* The Fund's total return for the year, based on the market price of its stock, was 34.6%.*
New Studies of Electron Beam Radiation Treatment Show Women Can Get a One Day Treatment for Their Breast Cancer and Nearly All Breast Cancer Patients Can Benefit
Business Wire - Thu Dec 12, 2:44PM CST
The recent release of comprehensive, multi-year studies of thousands of cancer patients out of Europe demonstrate clearly the substantial advantages for the use of intraoperative electron-beam radiation therapy techniques in providing significantly improved clinical outcomes and psychological benefits to breast cancer patients. Most experts agree that intraoperative electron radiation treatment (IOERT) is beneficial in the treatment of many locally advanced and recurrent cancers. These studies are the first to clearly demonstrate that IOERT will also have a major role in the treatment of breast cancer. www.intraopmedical.com.
Firsthand Technology Value Fund Discloses Top Holdings
GlobeNewswire - Fri Dec 06, 11:45AM CST
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund", a publicly-traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of November 30, 2013 were Twitter, Facebook, IntraOp Medical, AliphCom, and Sunrun.
Firsthand Technology Value Fund Discloses Preliminary NAV of $27.43 Per Share as of March 31, 2014
GlobeNewswire - Thu Apr 17, 12:02PM CDT
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund"
, a publicly-traded venture capital fund that invests in technology and cleantech companies, today disclosed its preliminary net asset value (NAV) of $27.43 per share, as of March 31, 2014. Firsthand Technology Value Fund Discloses Top Portfolio Holdings
GlobeNewswire - Mon Mar 10, 9:01AM CDT
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund"
, a publicly-traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2014 were Twitter, Facebook, IntraOp Medical, Turn, and AliphCom. Firsthand Technology Value Fund Discloses Preliminary NAV of $28.31 Per Share as of December 31, 2013
GlobeNewswire - Thu Jan 16, 8:00AM CST
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund"
, a publicly-traded venture capital fund that invests in technology and cleantech companies, today disclosed its preliminary net asset value (NAV) of $28.31 per share, as of December 31, 2013. The Fund's estimated total return for 2013, based on the December 31, 2013 preliminary NAV, was 25.3%.* The Fund's total return for the year, based on the market price of its stock, was 34.6%.* New Studies of Electron Beam Radiation Treatment Show Women Can Get a One Day Treatment for Their Breast Cancer and Nearly All Breast Cancer Patients Can Benefit
Business Wire - Thu Dec 12, 2:44PM CST
The recent release of comprehensive, multi-year studies of thousands of cancer patients out of Europe demonstrate clearly the substantial advantages for the use of intraoperative electron-beam radiation therapy techniques in providing significantly improved clinical outcomes and psychological benefits to breast cancer patients. Most experts agree that intraoperative electron radiation treatment (IOERT) is beneficial in the treatment of many locally advanced and recurrent cancers. These studies are the first to clearly demonstrate that IOERT will also have a major role in the treatment of breast cancer. www.intraopmedical.com.
Firsthand Technology Value Fund Discloses Top Holdings
GlobeNewswire - Fri Dec 06, 11:45AM CST
Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the "Fund"
, a publicly-traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of November 30, 2013 were Twitter, Facebook, IntraOp Medical, AliphCom, and Sunrun. 
